From:
xxxxxx@lists.healthresearch.org <xxxxxx@lists.healthresearch.org> on behalf of Motoki, Connie <xxxxxx@wustl.edu>
Date: Wednesday, September 27, 2023 at 12:28 PM
To: xxxxxx@lists.healthresearch.org <xxxxxx@lists.healthresearch.org>
Subject: RE: [RESADM-L] supplement subaward and indirects
Great topic:
Our sponsored program office managers were just discussing this and searching NIH last week for documentation on how to
treat supplemental funding.
Washington University has adapted the practice of setting up new subawards for supplemental projects, and we take the F&A on each sub under
a supplement award. In my experience, the NOA often requires a separate accounting of the supplemental funds.
See what I found:
Funding Opportunity Title
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Activity Code
Administrative Supplement
Additional funds may be awarded as supplements to parent awards for all activity codes.
Announcement Type
Reissue of PA-18-591
3. Reporting
Reporting requirements will be specified in the terms and conditions of award as applicable to the supplemental activities.
In most non-competing continuation applications, the progress report and budget for the supplement must be included with, but clearly delineated from, the progress report and budget for the parent award.
We’ve interpreted this to track separately the supplemental award expenses, including any subawards.
Thank you,
Connie
From: xxxxxx@lists.healthresearch.org <xxxxxx@lists.healthresearch.org>
On Behalf Of Lacey Rhea
Sent: Monday, September 18, 2023 8:59 AM
To: xxxxxx@lists.healthresearch.org
Subject: Re: [RESADM-L] supplement subaward and indirects
Great question that I can’t believe isn’t covered by an NIH FAQ, it comes up so often. My understanding is that the $25k doesn't reset for each activity. Though it is a separate scope of work, it is still
one subaward relationship under one NIH award. The compartmentalizing of it into separate buckets is an internal choice; from the NIH's perspective it is all one pot of money.
I can't seem to find anything in UG or NIH that addresses this exactly, but past experience informs my opinion, and here are some institutional interpretations that agree:
And for fun, here is one that DOES NOT agree with me (though this seems specific to multiple-project awards such as the NIH P series):
And finally, here are previous listserv conversations on this topic, which also are not definitive (taken from the
RESADM-L Archives):
Best of luck.
Lacey Rhea
Research Administration Manager and Mentor
(c) 352-235-0756;
xxxxxx@gmail.com
LinkedIn:
https://www.linkedin.com/in/lacey-rhea
DISCLAIMER: The views expressed here are my own and not those of my employer.
This is probably an easy question for someone. We have a large NIH grant with a partner university; we are the lead and issue a subaward to our partner,
amending it annually. We have received several supplements to the large parent grant and issue subawards from the supplement (not amendments to the main parent grant subaward) to this same partner, so they now have more than one subaward under the same parent
grant. I was just asked by one of our accountants whether we could charge indirects on these separate subawards (which are for different activities).
My initial reaction was yes, because these are separate subawards and our base says “that portion of
each subaward in excess of $25,000”:

So separate subawards each max out at $25,000 for calculating indirects. But since the subs are all off the same parent grant, have I come to this
conclusion erroneously? Now I am doubting myself.
Thus, the question is: If you have multiple subawards to the same subrecipient off the same parent grant, can you charge indirects off each subaward?
I think I have overthought this and appreciate any guidance you can provide.
Carolyn
Carolyn Elliott-Farino, MA, CRA
(she/her)
Director, Research Grants
Authorized Organization Representative (AOR)
MaineHealth
Institute for Research
81 Research Drive, Scarborough, ME 04074
207-396-8188
xxxxxx@mainehealth.org
PATIENT CENTERED
|
RESPECT
|
INTEGRITY
|
EXCELLENCE
|
OWNERSHIP
|
INNOVATION
CONFIDENTIALITY NOTICE: This email message, including any attachments, is for the use of the intended recipient(s) only and may contain information that is privileged, confidential, and prohibited from unauthorized
disclosure under applicable law. If you are not the intended recipient of this message, any dissemination, distribution, or copying of this message is strictly prohibited. If you received this message in error, please notify the sender by reply email and destroy
all copies of the original message and attachments.
- = - = - = - = - = - = -
This email was sent to xxxxxx@gmail.com via the Research Administrator's mailing list.
To unsubscribe from RESADM-L, go to
https://lists.healthresearch.org and go into the Account Settings area.
List archives are available at:
https://lists.healthresearch.org/resadm-l
To change your settings (such as Digest Mode or to temporarily suspend list emails):
https://lists.healthresearch.org
- = - = - = - = - = - = -
This email was sent to xxxxxx@WUSTL.EDU via the Research Administrator's mailing list.
To unsubscribe from RESADM-L, go to
https://lists.healthresearch.org and go into the Account Settings area.
List archives are available at:
https://lists.healthresearch.org/resadm-l
To change your settings (such as Digest Mode or to temporarily suspend list emails):
https://lists.healthresearch.org
- = - = - = - = - = - = -
This email was sent to xxxxxx@sph.cuny.edu via the Research Administrator's mailing list.
To unsubscribe from RESADM-L, go to
https://lists.healthresearch.org and go into the Account Settings area.
List archives are available at:
https://lists.healthresearch.org/resadm-l
To change your settings (such as Digest Mode or to temporarily suspend list emails):
https://lists.healthresearch.org